Hepatitis A Clinical Trial
Official title:
Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age
Verified date | October 2016 |
Source | GlaxoSmithKline |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a study to evaluate the immune response and safety of GSK Biologicals 2-dose
inactivated hepatitis A vaccine when administered with a measles/mumps/rubella vaccine and a
varicella (chickenpox) vaccine in children as young as 15 months of age.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep
2007.
Status | Completed |
Enrollment | 1474 |
Est. completion date | June 9, 2009 |
Est. primary completion date | June 9, 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Months to 13 Months |
Eligibility |
Inclusion Criteria: - Subjects whose parents/guardians are believed by the investigator to be willing to comply with the requirements of the protocol - A male or female child 12 and 13 months of age at the time of entry into the Enrollment Phase - Written informed consent obtained from the parents or guardian of the subject, - Free of obvious health problems as established by medical history and history-directed physical examination before entering into the study, and - Parents/guardian of the subject must have a telephone or be able to be contacted by telephone Exclusion Criteria: - Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 42 days preceding the first dose of study vaccine, or planned use during the study period, Chronic administration (defined as more than 14 days) of immuno-suppressant or other immune-modifying drugs within six months prior to vaccination or planned administration at any time during the study period. (For corticosteroids, this will mean prednisone, or equivalent, =0.5 mg/kg/day. Inhaled, nasal and topical steroids are allowed.) Planned administration or administration of any vaccine not foreseen by the study protocol during the period 31 days before and 31 days after each dose of study vaccine(s). - Previous vaccination against hepatitis A, - History of hepatitis A, - Known exposure to hepatitis A, - Previous vaccination against measles, mumps, rubella and/or varicella, - History of measles, mumps, rubella and/or varicella, - Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to the start of the study, - Planned chronic use of salicylates during the 6-week period following administration of the doses of study vaccine(s), - Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection, - A family history of congenital, hereditary or infectious immunodeficiency or parental risk factors for HIV infection, - History of allergic disease/reactions or hypersensitivity likely to be exacerbated by any component of HavrixTM, M-M-RII or VARIVAXTM, including 2-phenoxyethanol, neomycin and gelatin, - History of anaphylactic or anaphylactoid reactions to egg proteins, - History of hypersensitivity/allergic reaction to latex. Note: The tip cap and the rubber plunger of the HavrixTM needleless pre-filled syringes contain dry natural latex rubber. - Major congenital defects or serious chronic illness, - Active untreated tuberculosis, - History of significant blood dyscrasias - History of any neurologic disorder (a history of febrile seizures not associated with an underlying neurological disorder does not exclude the subject) - Acute disease at the time of vaccination - Administration of immunoglobulins and/or any blood products within three months prior to the first dose of study vaccine or planned administration at any time during the entire study period |
Country | Name | City | State |
---|---|---|---|
United States | GSK Investigational Site | Albany | New York |
United States | GSK Investigational Site | Austin | Texas |
United States | GSK Investigational Site | Baltimore | Maryland |
United States | GSK Investigational Site | Beaver Falls | Pennsylvania |
United States | GSK Investigational Site | Bossier City | Louisiana |
United States | GSK Investigational Site | Bristol | Tennessee |
United States | GSK Investigational Site | Brooklyn | New York |
United States | GSK Investigational Site | Cabot | Arkansas |
United States | GSK Investigational Site | Cleveland | Ohio |
United States | GSK Investigational Site | Henderson | Nevada |
United States | GSK Investigational Site | Huntington Beach | California |
United States | GSK Investigational Site | Jacksonville | Florida |
United States | GSK Investigational Site | Jonesboro | Arkansas |
United States | GSK Investigational Site | Kingsport | Tennessee |
United States | GSK Investigational Site | Kingsport | Tennessee |
United States | GSK Investigational Site | Las Vegas | Nevada |
United States | GSK Investigational Site | Layton | Utah |
United States | GSK Investigational Site | Lexington | Kentucky |
United States | GSK Investigational Site | Lumberton | North Carolina |
United States | GSK Investigational Site | Marietta | Georgia |
United States | GSK Investigational Site | Marshfield | Wisconsin |
United States | GSK Investigational Site | Norfolk | Virginia |
United States | GSK Investigational Site | Norristown | Pennsylvania |
United States | GSK Investigational Site | North Little Rock | Arkansas |
United States | GSK Investigational Site | Norwich | Connecticut |
United States | GSK Investigational Site | Oakland | California |
United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
United States | GSK Investigational Site | Rochester | New York |
United States | GSK Investigational Site | Rolling Hills Estates | California |
United States | GSK Investigational Site | Rydal | Pennsylvania |
United States | GSK Investigational Site | San Antonio | Texas |
United States | GSK Investigational Site | Sellersville | Pennsylvania |
United States | GSK Investigational Site | South Jordan | Utah |
United States | GSK Investigational Site | Sylva | North Carolina |
United States | GSK Investigational Site | Syracuse | New York |
United States | GSK Investigational Site | Temple | Texas |
United States | GSK Investigational Site | Tulsa | Oklahoma |
United States | GSK Investigational Site | University Heights | Ohio |
United States | GSK Investigational Site | Warwick | Rhode Island |
United States | GSK Investigational Site | Waterloo | Iowa |
United States | GSK Investigational Site | Waukee | Iowa |
Lead Sponsor | Collaborator |
---|---|
GlaxoSmithKline |
United States,
Rinderknecht S, Michaels MG, Blatter M, Gaglani M, Andrews W, Abughali N, Chandreshekaran V, Trofa AF. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age. Pediatr Infect Dis J. 2011 Oct;30(10):e179-85. doi: 10.1097/INF.0b013e31822256a5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups. | Concentrations are given as geometric mean concentrations (GMCs) expressed as milli-international units per milliliter (mIU/mL). | 31 days following the second dose of Havrix® | |
Primary | Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups | Anti-HAV antibody cut-off value assessed include 15 milli-international units per milliliter (mIU/mL). | 31 days following the second dose of Havrix® | |
Primary | Number of Subjects Seroconverted for Anti-measle, Anti-mumps and Anti-varicella Antibodies in HAV+MMR+V and MMR+V?HAV Groups | Seroconversion is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off values assessed include 150 milli-international units per milliliter (mIU/mL) for anti-measles antibodies, 28 Effective Dose 50 (ED50) for anti-mumps antibodies and 1:5 for anti-varicella antibodies. | 42 days following the administration of M-M-R®II and VARIVAX® | |
Primary | Number of Subjects With Vaccine Response for Anti-rubella Antibodies in HAV+MMR+V and MMR+V?HAV Groups | Vaccine response is defined as the appearance of antibodies with titers greater than or equal to the predefined cut-off value in the serum of subject seronegative before vaccination. Cut-off value assessed include 10 milli-international units per milliliter (mIU/mL). | 42 days following administration of M-M-R®II and VARIVAX® | |
Secondary | Anti-measles, Anti-mumps, Anti-rubella and Anti-varicella Antibody Titers in HAV+MMR+V and MMR+V?HAV Groups | Titers are given as geometric mean titers (GMTs). | 42 days following the administration of M-M-R®II and VARIVAX® | |
Secondary | Anti-hepatitis A Virus (HAV) Antibody Concentrations in HAV and HAV+MMR+V Groups | Concentrations are given as geometric mean concentrations (GMCs). | 42 days following the first dose of Havrix® | |
Secondary | Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentration Equal or Above the Cut-off Value in HAV and HAV+MMR+V Groups | Anti-HAV antibody cut-off value assessed include 15 milli-international units per millilitre (mIU/mL). | 42 days following the first dose of Havrix® | |
Secondary | Anti-hepatitis A Virus (HAV) Antibody Concentrations in MMR+V?HAV Group | Concentrations are given as geometric mean concentrations (GMCs). | 31 days following the second dose of Havrix® | |
Secondary | Number of Subjects With Anti-hepatitis A Virus (HAV) Antibody Concentrations Above the Cut-off Value in MMR+V?HAV Group | Anti-HAV antibody cut-off value assessed include 15 milli-international units per millilitre (mIU/mL). | 31 days following the second dose of Havrix® | |
Secondary | Number of Subjects With Vaccine Response to Havrix® | Vaccine response was defined as: 1) a detectable anti-hepatitis A virus (HAV) antibody concentration 31 days following the second dose in subjects who were initially seronegative; and 2) a 2-fold increase in anti-HAV antibody concentrations above the pre-study concentration 31 days following the second dose in subjects who were initially seropositive. | 31 days following the second dose of Havrix® | |
Secondary | Number of Subjects Reporting Solicited Local Symptoms | Solicited local symptoms assessed include pain, rash (local), redness and swelling. | During the 4-day period following each dose of vaccine | |
Secondary | Number of Subjects Reporting Solicited General Symptoms | Solicited general symptoms assessed include drowsiness, fever, irritability, loss of appetite and rash (general). | During the 4-day period following each dose of vaccine | |
Secondary | Number of Subjects Reporting Measles, Mumps, Rubella and Varicella Specific Solicited General Adverse Events | Specific adverse events assessed include papules, vesicles, crusts, parotid/salivary gland swelling and suspected signs of meningitis/febrile seizures. | During the 43-day period following each dose of vaccine | |
Secondary | Number of Subjects Reporting Unsolicited Adverse Events (AEs) | Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms | During the 31-day period following each dose of vaccine | |
Secondary | Number of Subjects Reporting Serious Adverse Events (SAEs) | SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. | During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end) | |
Secondary | Number of Subjects Reporting New Chronic Illnesses | New Chronic illnesses include autoimmune disorders, asthma, type I diabetes, allergies. | During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end) | |
Secondary | Number of Subjects Reporting Medically Significant Events | Medically significant events include, but are not limited to, diabetes, autoimmune disease, asthma, allergies and/or conditions prompting emergency room or physician office visits that are not related to well-child care, vaccination or common acute illnesses (e.g., upper respiratory infection, otitis media, pharyngitis, gastroenteritis, injury and visits for routine physical examination). | During the Active Phase (from Day 0 up to Day 31 after the second dose) and the Extended Safety Follow-up Phase of the study (from Day 31 after the second dose up to study end) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03445416 -
Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men
|
N/A | |
Completed |
NCT01949857 -
The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines
|
Phase 4 | |
Completed |
NCT00313950 -
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
|
Phase 4 | |
Completed |
NCT00197171 -
Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine
|
Phase 3 | |
Completed |
NCT00139139 -
A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A
|
N/A | |
Completed |
NCT00139113 -
Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children
|
Phase 4 | |
Completed |
NCT03312699 -
Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort
|
Phase 1 | |
Completed |
NCT03855176 -
Effectiveness of Booster With 1 or 2 Doses of HAV Vaccine Among HIV-infected Patients
|
Phase 4 | |
Completed |
NCT00197002 -
Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age
|
Phase 3 | |
Withdrawn |
NCT02605538 -
Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
|
N/A | |
Completed |
NCT04638335 -
What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years
|
||
Active, not recruiting |
NCT06058416 -
Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old
|
Phase 4 | |
Completed |
NCT01453348 -
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
|
Phase 3 | |
Completed |
NCT02002065 -
The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children
|
N/A | |
Completed |
NCT01865968 -
Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults
|
Phase 4 | |
Terminated |
NCT00119743 -
A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine
|
Phase 3 | |
Completed |
NCT01000324 -
Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult
|
Phase 4 | |
Completed |
NCT00289731 -
Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc
|
Phase 4 | |
Completed |
NCT02300792 -
The Effects of Honey, as a Dietary Supplement in Children With Hepatitis A
|
Phase 2 | |
Completed |
NCT02601040 -
Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines
|
Phase 4 |